Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine

Synapse

Volumn 63, Issue 10, 2009, Pages 913-920

  Jardemark, Kent E ^a   Konradsson, Åsa ^a   Schilström, Björn ^a   Marcus, Monica M ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Clozapine; Medial prefrontal cortex; NMDA; Schizophrenia; Topiramate

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; RACLOPRIDE; TOPIRAMATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; MALE; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; RECEPTOR BLOCKING; SCHIZOPHRENIA; SYMPTOM;

ANIMALS; BIOPHYSICAL PROCESSES; CLOZAPINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; EXCITATORY POSTSYNAPTIC POTENTIALS; FRUCTOSE; GLUTAMIC ACID; MALE; MEMBRANE POTENTIALS; N-METHYLASPARTATE; NEUROPROTECTIVE AGENTS; PATCH-CLAMP TECHNIQUES; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS; SYNAPTIC TRANSMISSION;

EID: 70349146283     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20674     Document Type: Article

References (45)

1. Allison DB, Casey DE. 2001. Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry 62 (Suppl 7):22-31. (Pubitemid 32402182)
2. Arnone D. 2005. Review of the use of Topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 4:5. (Pubitemid 40854397)
3. Arvanov VL, Wang RY. 1998. M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate- receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18:197-209. (Pubitemid 28062583)
4. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. 1997. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234. (Pubitemid 27438966)
5. Biton V, Edwards KR, Montouris GD, Sackellares JC, Harden CL, Kamin M. 2001. Topiramate titration and tolerability. Ann Pharmacother 35:173-179.
6. Camperi M, Wang XJ. 1998. A model of visuospatial working memory in prefrontal cortex: Recurrent network and cellular bistability. J Comput Neurosci 5:383-405. (Pubitemid 28554680)
7. Chen L, Yang CR. 2002. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87:2324-2336. (Pubitemid 34670705)
8. Daly DA, Moghaddam B. 1993. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152:61-64. (Pubitemid 23149313)
9. Deutsch SI, Rosse RB, Billingslea EN, Bellack AS, Mastropaolo J. 2002. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur J Pharmacol 449:121-125. (Pubitemid 34887999)
10. Deutsch SI, Schwartz BL, Rosse RB, Mastropaolo J, Marvel CL, Drapalski AL. 2003. Adjuvant topiramate administration: A pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol 26:199-206. (Pubitemid 36951066)
11. Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI. 2001. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 24:290-294.
12. Durstewitz D, Seamans JK, Sejnowski TJ. 2000. Neurocomputational models of working memory. Nat Neurosci 3 (Suppl):1184-1191.
13. Dursun SM, Devarajan S. 2000. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 45:198. (Pubitemid 30238116)
14. Dursun SM, Deakin JF. 2001. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study. J Psychopharmacol 15:297-301.
15. Eltayb A, Wadenberg ML, Schilstrom B, Svensson TH. 2005. Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride. Naunyn Schmiedebergs Arch Pharmacol 372:195-202. (Pubitemid 41668749)
16. Ganguli R. 1999. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 60 (Suppl 21):20-24. (Pubitemid 29523629)
17. Jardemark K, Marcus MM, Konradsson A, Svensson TH. 2005. The combination of nicotine with the D2 antagonist raclopride or the weak D4 antagonist L-745870 generates a clozapine-like facilitation of NMDA receptor-mediated neurotransmission in pyramidal cells of the rat medial prefrontal cortex. Int J Neuropsychopharmacol 8:157-162. (Pubitemid 40769256)
18. Kanner AM, Wuu J, Faught E, Tatum W, Fix A, French JA. 2003. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4:548-552. (Pubitemid 37407613)
19. Khan A, Faught E, Gilliam F, Kuzniecky R. 1999. Acute psychotic symptoms induced by topiramate. Seizure 8:235-237. (Pubitemid 29401589)
20. Ko YH, Joe SH, Jung IK, Kim SH. 2005. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 28:169-175. (Pubitemid 41134243)
21. Konradsson A, Marcus MM, Hertel P, Svensson TH, Jardemark KE. 2006. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 60:102-108. (Pubitemid 43878118)
22. Kuroki T, Meltzer HY, Ichikawa J. 1999. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781. (Pubitemid 29119694)
23. Lessig MC, Shapira NA, Murphy TK. 2001. Topiramate for reversing atypical antipsychotic weight gain. J Am Acad Child Adolesc Psychiatry 40:1364. (Pubitemid 34250952)
24. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, Montrose D. 2008. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia Am J Psychiatry 165:1585-1593.
25. Lin YH, Liu CY, Hsiao MC. 2005. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci 59:613-615. (Pubitemid 41765763)
26. Mathe JM, Nomikos GG, Schilstrom B, Svensson TH. 1998. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res 51:583-592. (Pubitemid 28115059)
27. Marcus MM, Jardemark KE, Wadenberg ML, Langlois X, Hertel P, Svensson TH. 2005. Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment. Int J Neuropsychopharmacol 8:315-327.
28. Maurer TS, Debartolo DB, Tess DA, Scott DO. 2005. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181.
29. Meltzer HY, McGurk SR. 1999. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255.
30. Millson RC, Owen JA, Lorberg GW, Tackaberry L. 2002. Topiramate for refractory schizophrenia. Am J Psychiatry 159:675.
31. Moghaddam B, Bunney BS. 1990. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J Neurochem 54:1755-1760. (Pubitemid 20136740)
32. Mula M, Trimble MR, Lhatoo SD, Sander JW. 2003. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44:659-663. (Pubitemid 36554633)
33. Ninan I, Wang RY. 2003. Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: Pharmacological evidence. Eur J Neurosci 17:1306-1312. (Pubitemid 36459786)
34. Ninan I, Jardemark KE, Wang RY. 2003. Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48:66-79. (Pubitemid 36374000)
35. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH. 1994. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl) 115:147-156. (Pubitemid 24207775)
36. Shaldubina A, Einat H, Szechtman H, Shimon H, Belmaker RH. 2002. Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm 109:433-440. (Pubitemid 34251645)
37. Shu Y, Hasenstaub A, McCormick DA. 2003. Turning on and off recurrent balanced cortical activity. Nature 423:288-293. (Pubitemid 40852698)
38. Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E. 2001. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 153:238-243. (Pubitemid 32127893)
39. Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvarinen S, Eronen M, Putkonen H, Takala P, Mehtonen OP, Puck M, Oksanen J, Koskelainen P, Joffe G, Aer J, Hallikainen T, Ryynanen OP, Tupala E. 2005. Topiramate add-on in treatment-resistant schizophrenia: A randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 66:1012-1015. (Pubitemid 41191793)
40. Wadenberg ML, Hicks PB. 1999. The conditioned avoidance response test re-evaluated: Is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862.
41. Wang XJ. 1999. Synaptic basis of cortical persistent activity: The importance of NMDA receptors to working memory. J Neurosci 19:9587-9603.
42. Westerink BH, Kawahara Y, De Boer P, Geels C, De Vries JB, Wikstrom HV, Van Kalkeren A, Van Vliet B, Kruse CG, Long SK. 2001. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 412:127-138. (Pubitemid 32124859)
43. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. 1997. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28:167-179.
44. Wittmann M, Marino MJ, Henze DA, Seabrook GR, Conn PJ. 2005. Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: Role of NR2B and protein kinase A/Src kinases. J Pharmacol Exp Ther 313:594-603. (Pubitemid 40604159)
45. Wu WR, Li N, Sorg BA. 2002. Regulation of medial prefrontal cortex dopamine by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptors. Neuroscience 114:507-516. (Pubitemid 35245428)